Selected Research, Abstracts and Poster Presentations
- To Mix or Not to Mix? A Preliminary Report of the Effect of Mixing on the Pharmacodynamics of Insulin Aspart and Detemir by a team from Yale University found that "... mixing of insulin aspart with insulin detemir is associated with a flattening and prolongation of the time-action profile compared to when these insulin analogs are given as separate injections." For insulin pen users, mixing is not an issue, but in the US many kids who are on injection therapy use syringes and insulin vials and thus are able to mix. If your child uses NovoLog (aspart) and Levemir (detemir) and you mix the insulins, you should be aware of the blunting effect as reported in this poster.
- In Twenty Years of Multiple Daily Injections from the Onset of Diabetes in Children and Adolescents, Dr. Ragnar Hanas and a team from Sweden review data from 1985 looking at the risk of complications and the risk of severe hypoglycemia. They found "... for this non-selected patient group using MDI from the onset of diabetes has a low risk of long-term complications with an acceptable rate of severe hypoglycemia."
- In Feasibility of Continuous Subcutaneous Insulin Infusion and Daily Supplemental Insulin Glargine Injection in Pediatric Type 1 Diabetes, a team from Milwaukee, Wisconsin found that adding a daily injection of glargine (Lantus) with insulin pump therapy did not increase the risk of hypoglycemia and "... may serve as a preventive measure in young children at risk of developing hyperglycemia and ketosis or DKA due to catheter dislodgement, insulin pump malfunction and/or temporary pump suspension."
- In Sweetened Soda Intake and CVD Risk Factors in Youth with Type 1 Diabetes, a large group of authors found that "... high sweetened soda intake as contrasted to no- and moderate intake is associated with higher levels of CVD risk factors in youth with T1DM." As we look to educate our children on healthy eating habits, the data reported in this poster offer us guidance on the importance of reducing or eliminating sugared soft drinks from the diets of our children with diabetes.
- In a poster entitled Hyperglycemia Associated with Brain Volume Changes Over Time in Youth with Type 1 Diabetes Mellitus (T1DM), a team from St. Louis reported that whole brain scanning has shown that "... greater exposure to hyperglycemia was associated with measurable differences in gray and white matter development in youth with T1DM over a 2-year time period." While some previous research has tried to look at the impact of hypoglycemia on brain development, this team focused on hyperglycemia. These kinds of studies emphasize the importance of good control regardless of age.
- In a poster entitled Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Pramlintide in Adolescent Subjects with Type 1 Diabetes, authors from the Barbara Davis Center in Denver, led by Dr. Peter Chase, reported on the use of Symlin (pramlintide) in youth aged 12 to 17 with type 1 diabetes. The study found that pramlintide works the same in teens as it does in adults, and results in decreased postprandial excursions, suppressed postprandial glucagon, and delayed gastric emptying. Parents whose teens are struggling with postprandial highs in spite of pre-bolusing and reduction in meal carbohydrates may wish to discuss the use of pramlintide with their diabetes team.
- In a poster entitled School Centered Telemedicine Study for Children with Diabetes, authors from SUNY Upstate Medical University and the VA Medical Center in Syracuse, New York examined whether using telemedicine technology in a school setting would improve outcomes for school aged kids with type 1 diabetes. Twenty-five elementary and middle schools were involved, covering 23 students in the intervention and 18 controls for a total of 41 students. At the end of the 12-month study period, kids receiving telemedicine support had lower HbA1c readings, improvement in emotional functioning, and very importantly the number of urgent diabetes-related calls to the diabetes center dropped significantly.
Products and Product News
With the FreeStyle Navigator® now approved for sale in the United States, Abbott Diabetes Care proudly showed it within their booth. Several members of Team Type 1 rode a stationary bicycle in the booth while wearing a Navigator. The receiver was on a nearby table and the image of the display was captured via a video camera and displayed for passersby to see. We could watch in real time as the rider's blood sugar dropped in response to their vigorous riding. The demonstration was very effective. We have a photo of Monique Hanley while riding.
New Accu-Chek® Compact Plus
Roche showed a redesigned Accu-Chek® Compact Plus meter. Like a lot of updated meters, the design is much less "medical" and much more like a consumer electronics device, which is great for people living with diabetes. The display is larger too, which helps those of us with aging eyes. The Accu-Chek Compact Plus remains the only all-in-one glucose meter that you can use with just one hand.
Bayer Contour in Color
Bayer Health Care showed a newly designed Contour® glucose meter. Dropping the Ascensia name, the meter simply says "Contour" and offers no-coding and two levels of display -- a basic level for people who don't want to see all the features and an advanced level typical of what children with diabetes and their parents want in a meter (memories, averages, etc.). The new Contour also comes in four colors, again a nod to the growing importance of design in personal medical devices.
Afinion Point-of-Care HbA1c Analyzer
Abbott Diabetes Care showed the Afinion point-of-care HbA1c analyzer. CLIA waved, the Afinion affers a three-minute HbA1c result as well as a five-minute albumin-creatinine ratio result. The Abbott representative noted that the Afinion is auto-calibrated, making it easier to use than similar doctor's office devices, and is priced competetively. See also Axis-Shield PoC - Afinion HbA1c Test.
|Return to the Top of This Page|
Last Updated: Tuesday December 08, 2009 12:34:16
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.